Levetiracetam in three cases of progressive myoclonus epilepsy.
We present three unrelated cases of genetically confirmed progressive myoclonic epilepsy of the Unverricht-Lundborg type who were treated with Levetiracetam as adjunctive therapy for their myoclonus. All cases responded with decrease of their myoclonus and improvement of quality of life. Two were able to return to or continue their employment. Patients tolerated the drug well without side effects reported. Levetiracetam appears to be a useful antimyoclonic agent in cases of progressive myoclonic epilepsy and should be considered for adjunctive therapy.
Papacostas
Savvas
S
The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus. savvas@cing.ac.cy
Kkolou
Elena
E
Papathanasiou
Eleftherios
E
D000203:Activities of Daily Living; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000077287:Levetiracetam; D008297:Male; D010889:Piracetam / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D011788:Quality of Life; D012720:Severity of Illness Index; D016896:Treatment Outcome; D020194:Unverricht-Lundborg Syndrome / Q000188:drug therapy*
D000927:Anticonvulsants; D000077287:Levetiracetam; D010889:Piracetam